Erratum (DOI:10.1053/j.ajkd.2007.08.015);Treatment of Peritoneal Dialysis-Associated Peritonitis: A Systematic Review of Randomized Controlled Trials

American Journal of Kidney Diseases

Volumn 50, Issue 6, 2007, Pages 967-988

  Wiggins, Kathryn J ^a   Johnson, David W ^a   Craig, Jonathan C ^b   Strippoli, Giovanni F M ^b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b University of Sydney   (Australia)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Antimicrobial agents; peritoneal dialysis; peritoneal lavage; peritonitis; urokinase

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; FIBRINOLYTIC AGENT; GENTAMICIN; IMIPENEM; IMMUNOGLOBULIN; LEVOFLOXACIN; NETILMICIN; OFLOXACIN; PEFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TOBRAMYCIN; UROKINASE; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; ARTICLE; CATHETER REMOVAL; CONTINUOUS INFUSION; CONVULSION; DIALYSIS; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; ERADICATION THERAPY; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; NAUSEA; PERITONEAL DIALYSIS; PERITONEUM LAVAGE; PERITONITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SEIZURE; SYSTEMATIC REVIEW; TREATMENT FAILURE; VOMITING;

EID: 36248983168     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.07.001     Document Type: Erratum

References (76)

1. Voinescu C.G., and Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 25 (2002) 249-260
2. Bazzato G., Landini S., Coli U., Lucatello S., Fracasso A., and Moracchiello M. A new technique of continuous ambulatory peritoneal dialysis (CAPD): Double-bag system for freedom to the patient and significant reduction of peritonitis. Clin Nephrol 13 (1980) 251-254
3. Monteon F., Correa-Rotter R., Paniagua R., et al. Prevention of peritonitis with disconnect systems in CAPD: A randomized controlled trial. The Mexican Nephrology Collaborative Study Group. Kidney Int 54 (1998) 2123-2128
4. Strippoli G.F., Tong A., Johnson D., Schena F.P., and Craig J.C. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: A systematic review of randomized, controlled trials. J Am Soc Nephrol 15 (2004) 2735-2746
5. Kawaguchi Y. National comparisons: Optimal peritoneal dialysis outcomes among Japanese patients. Perit Dial Int 19 suppl 3 (1999) S9-S16
6. Grunberg J., Verocay M.C., Rebori A., et al. Twenty years' pediatric chronic peritoneal dialysis in Uruguay: Patient and technique survival. Pediatr Nephrol 20 (2005) 1315-1319
7. Oxton L.L., Zimmerman S.W., Roecker E.B., and Wakeen M. Risk factors for peritoneal dialysis-related infections. Perit Dial Int 14 (1994) 137-144
8. Juergensen P.H., Gorban-Brennan N., Troidle L., and Finkelstein F.O. Racial differences and peritonitis in an urban peritoneal dialysis center. Adv Perit Dial 18 (2002) 117-118
9. Lim W.H., Johnson D.W., and McDonald S.P. Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: Analysis of ANZDATA. Nephrology (Carlton) 10 (2005) 192-197
10. McDonald S.P., Collins J.F., Rumpsfeld M., and Johnson D.W. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 24 (2004) 340-346
11. Alves F.R., Dantas R.C., and Lugon J.R. Higher incidence of catheter-related infections in a tropical climate. Adv Perit Dial 9 (1993) 244-247
12. Szeto C.C., Chow K.M., Wong T.Y., Leung C.B., and Li P.K. Influence of climate on the incidence of peritoneal dialysis-related peritonitis. Perit Dial Int 23 (2003) 580-586
13. Troidle L., Watnick S., Wuerth D.B., Gorban-Brennan N., Kliger A.S., and Finkelstein F.O. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis 42 (2003) 350-354
14. Oo T.N., Roberts T.L., and Collins A.J. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 45 (2005) 372-380
15. Huang J.W., Hung K.Y., Yen C.J., Wu K.D., and Tsai T.J. Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis. Nephrol Dial Transplant 16 (2001) 604-607
16. Smit W., van den Berg N., Schouten N., Aikens E., Struijk D.G., and Krediet R.T. Free-water transport in fast transport status: A comparison between CAPD peritonitis and long-term PD. Kidney Int 65 (2004) 298-303
17. Ates K., Koc R., Nergizoglu G., et al. The longitudinal effect of a single peritonitis episode on peritoneal membrane transport in CAPD patients. Perit Dial Int 20 (2000) 220-226
18. Davies S.J., Bryan J., Phillips L., and Russell G.I. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11 (1996) 498-506
19. Coles G.A., and Topley N. Long-term peritoneal membrane changes. Adv Ren Replace Ther 7 (2000) 289-301
20. Kawanishi H., Watanabe H., Moriishi M., and Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 25 suppl 4 (2005) S39-S47
21. Rigby R.J., and Hawley C.M. Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 13 (1998) 154-159
22. Fried L.F., Bernardini J., Johnston J.R., and Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7 (1996) 2176-2182
23. Choi P., Nemati E., Banerjee A., Preston E., Levy J., and Brown E. Peritoneal dialysis catheter removal for acute peritonitis: A retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 43 (2004) 103-111
24. Heaf J. Underutilization of peritoneal dialysis. JAMA 291 (2004) 740-742
25. Pickering S.J., Fleming S.J., Bowley J.A., et al. Urokinase: A treatment for relapsing peritonitis due to coagulase-negative staphylococci. Nephrol Dial Transplant 4 (1989) 62-65
26. Innes A., Burden R.P., Finch R.G., and Morgan A.G. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: A double-blind clinical trial. Nephrol Dial Transplant 9 (1994) 797-799
27. Ejlersen E., Brandi L., Lokkegaard H., Ladefoged J., Kopp R., and Haarh P. Is initial (24 hours) lavage necessary in treatment of CAPD peritonitis?. Perit Dial Int 11 (1991) 38-42
28. Piraino B., Bailie G.R., Bernardini J., et al. Peritoneal dialysis-related infections recommendations: 2005 Update. Perit Dial Int 25 (2005) 107-131
29. CARI: The CARI Guidelines (Caring for Australians with Renal Impairment). Nephrology (Carlton) 9 suppl 3 (2004) S41-S106
30. Passadakis P., and Oreopoulos D. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis. Adv Perit Dial 17 (2001) 180-190
31. Fielding R.E., Clemenger M., Goldberg L., and Brown E.A. Treatment and outcome of peritonitis in automated peritoneal dialysis, using a once-daily cefazolin-based regimen. Perit Dial Int 22 (2002) 345-349
32. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
33. Bennett-Jones D., Wass V., and Mawson P. A comparison of intraperitoneal and intravenous/oral antibiotics in CAPD peritonitis. Perit Dial Bull 7 (1987) 31-33
34. Bailie G.R., Morton R., Ganguli L., Keaney M., and Waldek S. Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated gram-positive peritonitis?. Nephron 46 (1987) 316-318
35. Bennett-Jones D.N., Russell G.I., and Barrett A. A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. J Antimicrob Chemother 26 suppl F (1990) S73-S76
36. Cheng I., Lui S., Fang G., et al. A randomised prospective comparison of oral versus intraperitoneal ofloxacin as the primary treatment of CAPD peritonitis. Nephrology 3 (1997) 431-435
37. Cheng I.K., Chan C.Y., Wong W.T., et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 13 suppl 2 (1993) S351-S354
38. Gucek A., Bren A.F., Lindic J., Hergouth V., and Mlinsek D. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients?. Adv Perit Dial 10 (1994) 144-146
39. Lye W.C., Lee E.J., and van der Straaten J. Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 13 suppl 2 (1993) S348-S350
40. Tapson J.S., Orr K.E., George J.C., Stansfield E., Bint A.J., and Ward M.K. A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. J Antimicrob Chemother 26 suppl F (1990) S63-S71
41. Cheng I.K., Chan C.Y., and Wong W.T. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 11 (1991) 27-30
42. Chan M.K., Cheng I.K., and Ng W.S. A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 15 (1990) 155-159
43. Cheng I.K., Fang G.X., Chau P.Y., et al. A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. Perit Dial Int 18 (1998) 371-375
44. Boeschoten E.W., Rietra P.J., Krediet R.T., Visser M.J., and Arisz L. CAPD peritonitis: A prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 16 (1985) 789-797
45. Bowley J.A., Pickering S.J., Scantlebury A.J., Ackrill P., and Jones D.M. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 21 suppl A (1988) S133-S139
46. Friedland J.S., Iveson T.J., Fraise A.P., Winearls C.G., Selkon J.B., and Oliver D.O. A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother 26 suppl F (1990) S77-S81
47. Gucek A., Bren A.F., Hergouth V., and Lindic J. Cefazolin and netilmicin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. Adv Perit Dial 13 (1997) 218-220
48. Jimenez C., Selgas R., Sanchez S., et al. Initial empiric treatment of peritonitis in CAPD with vancomycin + tobramycin vs. vancomycin + cefotaxime in a CAPD unit. Nefrologia 16 (1996) 569A (abstr)
49. Wale M., Finch R., Morgan A., Burden R., and Holliday A. A prospective randomised trial of teicoplanin plus aztreonam versus cefuroxime in CAPD peritonitis. Int J Antimicrob Agents 1 suppl 1 (1992) S7-S14
50. Were A., Marsden A., Tooth A., Ramsden R., Mistry C., and Gokal R. Netilmycin and vancomycin in the treatment of peritonitis in CAPD patients. Clin Nephrol 37 (1992) 2009-2213
51. Flanigan M.J., and Lim V.S. Initial treatment of dialysis associated peritonitis: A controlled trial of vancomycin versus cefazolin. Perit Dial Int 11 (1991) 31-37
52. Wong K.M., Chan Y.H., Cheung C.Y., et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 38 (2001) 127-131
53. Schaefer F., Klaus G., Muller-Wiefel D.E., and Mehls O. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). J Am Soc Nephrol 10 (1999) 136-145
54. Anwar N., Merchant M., Were T., Tooth A., Uttley L., and Gokal R. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. Perit Dial Int 15 (1995) 167-171
55. Khairullah Q., Provenzano R., Tayeb J., Ahmad A., Balakrishnan R., and Morrison L. Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients. Perit Dial Int 22 (2002) 339-344
56. de Fijter C.W., ter Wee P.M., Oe L.P., and Verbrugh H.A. Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C)APD-related peritonitis: A prospective randomized multicenter comparison (CIPPER trial). Perit Dial Int 21 (2001) 480-486
57. Leung C.B., Szeto C.C., Chow K.M., et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis-A randomized controlled trial. Perit Dial Int 24 (2004) 440-446
58. Lui S.L., Cheng S.W., Ng F., et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: Effect on residual renal function. Kidney Int 68 (2005) 2375-2380
59. Lupo A., Rugiu C., Bernich P., et al. A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: Teicoplanin plus tobramycin versus cephalothin plus tobramycin. J Antimicrob Chemother 40 (1997) 729-732
60. Lye W.C., Wong P.L., van der Straaten J.C., Leong S.O., and Lee E.J. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv Perit Dial 11 (1995) 179-181
61. Velasquez-Jones L., Sanchez-Aguilar J., Castelares G., et al. Efficacy of intraperitoneal vancomycin in children on continuous ambulatory peritoneal dialysis: Comparison of intermittent and continuous therapy. Bol Med Hospital Infantil Mexico 52 (1995) 154-159
62. Boyce N.W., Wood C., Thomson N.M., Kerr P., and Atkins R.C. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis-A prospective, randomized comparison of intermittent v continuous therapy. Am J Kidney Dis 12 (1988) 304-306
63. Gadallah M.F., Tamayo A., Sandborn M., Ramdeen G., and Moles K. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. Adv Perit Dial 16 (2000) 233-236
64. Tong M.K., Leung K.T., Siu Y.P., et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. J Nephrol 18 (2005) 204-208
65. Williams A.J., Boletis I., Johnson B.F., et al. Tenckhoff catheter replacement or intraperitoneal urokinase: A randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. Perit Dial Int 9 (1989) 65-67
66. Coban E., Ozdogan M., Tuncer M., Bozcuk H., and Ersoy F. The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis. J Nephrol 17 (2004) 427-430
67. Milikin S.M.G., and Keane W.F. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int 11 (1991) 252-260
68. Kan G.W., Thomas M.A., and Heath C.H. A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: Is empiric vancomycin still indicated for some patients?. Perit Dial Int 23 (2003) 465-468
69. Booranalertpaisarn V., Eiam-Ong S., Wittayalertpanya S., Kanjanabutr T., and Na Ayudhya D.P. Pharmacokinetics of ceftazidime in CAPD-related peritonitis. Perit Dial Int 23 (2003) 574-579
70. Deamer R.L., and Dial L.K. The evolution of aminoglycoside therapy: A single daily dose. Am Fam Physician 53 (1996) 1782-1786
71. Grabe D.W., Bailie G.R., Eisele G., and Frye R.F. Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis 33 (1999) 111-117
72. Manley H.J., Bailie G.R., Asher R.D., Eisele G., and Frye R.F. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19 (1999) 65-70
73. Manley H.J., and Bailie G.R. Treatment of peritonitis in APD: Pharmacokinetic principles. Semin Dial 15 (2002) 418-421
74. O'Brien P.E., Tait N., and Bushell M. Management of diffuse peritonitis by prolonged postoperative peritoneal lavage. Aust N Z J Surg 57 (1987) 181-184
75. Carozzi S., Nasini M.G., Kunkl A., Cantarella S., and Lamperi S. Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy. ASAIO Trans 34 (1988) 635-639
76. Termorshuizen F., Korevaar J.C., Dekker F.W., van Manen J.G., Boeschoten E.W., and Krediet R.T. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41 (2003) 1293-1302